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Abstract
Background: Blood transfusion has always been an important route for Chagas Disease (CD)
transmission. The high prevalence of CD in Latin America and its lifelong asymptomatic clinical
picture pose a threat for the safety of the blood supply. The outcome of measures designed to
improve transfusion safety can be assessed by evaluating the prevalence of CD among
multitransfused patients
Methods: In order to assess the impact of CD control measures on the safety of the blood supply,
an observational cross-sectional study was designed to determine the prevalence of CD in 351
highly transfused patients, in which vectorial transmission was excluded. This study compared
patients that received transfusion products before (n = 230) and after (n = 121) 1997, when
measures to control transfusion-transmitted CD were fully implemented in Brazil.
Results: The study group consisted of 351 patients exposed to high numbers of blood products
during their lifetime (median number of units transfused = 51, range 10–2086). A higher prevalence
of transfusion-transmitted CD (1.30%) was observed among multitransfused patients that received
their first transfusion before 1997, compared with no cases of transfusion-transmitted CD among
multitransfused patients transfused after that year. The magnitude of the exposure to blood
products was similar among both groups (mean number of units transfused per year of exposure
= 25.00 ± 26.46 and 23.99 ± 30.58 respectively; P = 0.75, Mann-Whitney test).
Conclusion: Multiple initiatives aimed to control vector and parental transmission of CD can
significantly decrease transfusion-transmitted CD in Brazil. Our data suggest that mandatory donor
screening for CD represents the most important measure to interrupt transmission of CD by
blood transfusions.
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Background
Chagas disease (CD), caused by the protozoan Trypano-
soma cruzi is considered the most important parasitic dis-
ease of the Americas in terms of socioeconomic impact
[1]. Despite major improvements in the control of vecto-
rial transmission in endemic areas, CD still infects nearly
10 million people [2], and transfusions have always been
an important route of transmission [3]. Furthermore,
since most patients with CD are asymptomatic and una-
ware of their condition, these potential blood donors rep-
resent a serious threat to the safety of the blood supply of
non-endemic areas [4].
Since 1988, in Brazil as in many Latin American countries,
it is mandatory to screen blood donations for anti-T. cruzi
antibodies, and since 1997, 100% serological coverage
was reached in blood banks. [5]. Concomitantly, the con-
trol of vectorial transmission has significantly reduced the
prevalence of CD among blood donors [6].
One of the strategies used to assess blood supply safety is
to evaluate the prevalence of transfusion-transmitted
infections among multitransfused patients [7]. In contrast
to numerous studies on prevalence of to T. cruzi infection
among blood donors, only few reports have described its
prevalence among multitransfused patients, all of which
were published before donated blood started to be regu-
larly screened [8-10]. Therefore, the aim of this study was
(1) to assess the prevalence of CD among multitransfused
patients in Brazil, (2) to describe the changes in the prev-
alence over time, and (3) to describe the epidemiological
characteristics of transfusion-transmitted CD, with
emphasis on transfusion-related risk factors.
Methods
Three hundred and fifty-one multitransfused patients
were recruited from three health public institutions
located in the city of Campinas, Sao Paulo state, Brazil.
The metropolitan region of Campinas, with 3.2 million
inhabitants, is located in a non-endemic area of CD, in the
most densely populated region of Brazil. Informed con-
sent was obtained from all patients or legal guardian, and
the study was approved by the local Institution Review
Board. Patients were considered multitransfused if they
had been transfused with at least 10 units of blood prod-
ucts or blood derivatives divided between at least two
occasions, with the last occasion being at least 15 days
apart from recruitment date. One unit of blood product
was defined as 1 unit of whole blood, 1 unit of packed red
blood cells, 1 unit of a platelet concentrate or platelet
apheresis, 1 unit of plasma, 1 unit of cryoprecipitate
(Cryo) or 1 vial of lyophilized coagulation factor concen-
trate. Patients who were aware of a positive test for CD
before the first transfusion event were excluded from the
study. Clinical and epidemiological data were obtained
through a standard interview and from the patient's med-
ical records. This interview was performed by one member
of the team using a structured questionnaire after consent
was obtained. The questionnaire covered clinical and epi-
demiological details of the transfusion history of the
patients such as: diagnosis, type and number of blood
products used, date of first transfusion event and number
of facilities in which the patient was transfused. The ques-
tionnaire also included questions about alternative routes
for transmission of common blood-borne pathogens such
as intravenous drug use and previous history of invasive
medical interventions and/or alternative medical inter-
ventions. In order to exclude other routes of CD transmis-
sion in the study population, patients were questioned
about living in CD-endemic areas, in dwellings with mud/
mud-brick walls or known to be infested with triatomine
bugs. Patients were also questioned about relatives or
other household contacts with confirmed diagnosis of
CD.
Each calendar-year during which the patient received any
number of transfusions was recorded as one year of expo-
sure to transfusions. Donor exposure was estimated
assuming 1 unit:1 donor for all blood products, except
lyophilized factor concentrates that were not included in
this estimation, because of the assumption that T. cruzi
lose viability during the production of lyophilized clot-
ting factor concentrates. In fact, there are no reports of
transmission of CD by these types of blood products.
Blood samples were drawn at the day of recruitment.
Serum samples were tested in duplicate using an enzyme
immunoassay (Hemobio Chagas, Embrabio, São Paulo,
SP, Brazil), according to manufacturer's instructions. The
results of anti-T. cruzi test were expressed as the optical
densities of the samples (S) divided by the cut-off value
(C). S/C values ≤ 0.8 were considered seronegative, S/C
values between 0.8 and 1.2 were considered indetermi-
nate and S/C values ≥ 1.2 were considered seropositive.
Positive results were confirmed in a second sample, specif-
ically collected for to confirm these results, by immune-
fluorescence assay (Imuno Cruzi and Fluoline H, Biolab-
Meriéux, RJ, Brazil). For the purpose of this study, samples
were considered true positive if they were seropositive in
both tests.
The observed prevalence of CD was then calculated. To
estimate the impact on the safety of the blood supply of
the implementation of 100% coverage of serological
screening of CD among blood donors, January 1st 1997
was selected to define the experimental groups. The mean
number of units transfused per year of exposure was com-
pared using the Mann-Whitney test and a P < 0.05 was
considered significant.BMC Infectious Diseases 2008, 8:5 http://www.biomedcentral.com/1471-2334/8/5
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Results
Clinical characteristics and details of the transfusion his-
tory of the 351 eligible patients from the study are shown
in table 1. Three cases of transfusion-transmitted CD were
identified. None of of them presented additional risk fac-
tors for CD that might suggest an alternative route of
transmission. In fact, none of the patients in our study
presented additional epidemiological risk factors for CD
other than a history of blood transfusions. These 3 cases
represented a prevalence rate of CD of 1.30% among
patients who were first transfused before 1997, whereas
no cases of transfusion-transmitted CD were observed
among patients that were transfused only after 1997.
T. cruzi infected-patients included a hemophiliac who had
been transfused with whole blood, packed red blood cells
(PRBC), cryo and lyophilized factor concentrate since
1980 and two patients with hemoglobin diseases. The first
one is still under regular transfusion program with PRBC
(since 1975), and the other (Sβ Thal) was transfused only
two times (1971 and 1996). The patient with hemophilia
had only received factor concentrate after 1997 (table 2).
The mean number of units transfused per year of exposure
for these patients was 25.00 ± 26.46, compared to 23.99 ±
30.58 among seronegative patients (P = 0.75; Mann-Whit-
ney test).
Discussion
In this study we evaluated a population of 351 patients
exposed to an extremely high number of blood transfu-
sions for multiple reasons. The possibility of vectorial or
other forms of transmission of CD among seropositive
patients was discarded by the exclusion of patients with a
previous diagnosis of CD, and by an extensive interview
covering other known epidemiological risk factors for CD.
The laboratory strategy used to assess the prevalence of
CD was in agreement with current regulations established
by the Brazilian National Health Surveillance Agency for
the screening of blood donors for CD [11], and all posi-
tive samples were confirmed by an indirect immunofluo-
rescence test in a different sample. To our knowledge, this
is the first study to report the prevalence of CD among
multitransfused patients after the implementation of sero-
logical screening. Given the substantial social and eco-
nomical regional differences observed in Brazil, our
results cannot be extended to the whole country, where
prevalence rates and transmission patterns of CD are
expected to differ. However, the fact that this study was
conducted in an area without vectorial transmission
strengthens the association between our results and
changes in the risk for transfusion-transmitted CD.
The risk of transfusion-transmitted CD depends on five
factors: the prevalence of infection among blood donors,
the proportion of blood units actually screened in an area,
characteristics of the tests used, the risk of infection per
unit of blood transfused and the number of blood units
transfused [12]. Assuming that the risk of infection per
unit of blood transfused has not substantially changed
over time, and considering that the magnitude of expo-
sure to blood products in our study population was high,
both in terms of number of units (median 51, range 10 –
2086) and of length in years (median 3, range 1 – 52), we
can infer that the chance of acquiring CD among our
patients was largely dependent on the first 3 factors.
The main finding of our study was a clear difference in the
prevalence rate of CD between patients transfused before
and after 1997, with no new cases of transfusion-transmit-
ted CD in the latter group. This difference was observed
Table 1: Characteristics of patients included in the study (n = 351)
Age (Mean ± SD) 36.0 ± 19.8
Sex distribution (%)
Male 199 (56.7%)
Female 152 (43.3%)
Diagnosis responsible for multiple transfusions – number of patients (%)
Haemophilia 28 (8.0%)
Haemoglobinopathies 97 (27.6%)
Onco-haematological disease 184 (52.4%)
Acute blood loss 19 (5.4%)
Haemodyalisis 23 (6.6%)
Units transfused per patient (Median/Range) 51 (10–2086)
Years exposed to transfusions (Median/Range) 3 (1–52)
1st transfusion before 1997 (%) 230 (65.5%)
SD- standard deviation. Table 1 presents characteristics of the exposure to multiple transfusions in the study population, such as diagnosis 
responsible for transfusions and the magnitude of exposure to blood products in their lifetime. This magnitude is expressed both in terms of the 
number of blood products (units) and calendar-years during which the patients received blood transfusions. In addition, the table also shows the 
proportion of patients transfused before 1997, the year when multiple initiatives aimed to control transfusion-transmitted CD were fully 
implemented in Brazil.BMC Infectious Diseases 2008, 8:5 http://www.biomedcentral.com/1471-2334/8/5
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despite a similar number of blood products transfused per
year of exposure in both groups (25.00 ± 26.46 and 23.99
± 30.58 units in seropositive and seronegative patients
respectively; P = 0.75). Improvements in coverage and
quality of screening tests for CD are the most important
determinant of this change. Indeed, the proportion of
blood services performing at least one serological test for
CD increased from 69% in 1988 to 95.3% in 1990 in the
state of Sao Paulo [13], reaching 100% in 1997. Concom-
itantly, the sensitivity of screening tests, as well as alterna-
tive screening strategies using combinations of methods,
further decreased the risk of T. cruzi positive blood units
of entering in the blood supply [14]. Finally, the decreas-
ing prevalence of CD among blood donors during the last
decades, from a median above 2% reported in the 70's to
values in the range of 0.6–0.8% during the last 10 years,
are also a determinant of the observed results. In a study
with only first-time blood donors in the city of Sao Paulo,
the prevalence of CD was still decreasing at a significant
rate during the late 90's, from 0.47% in 1995 to 0.34% in
2001, with cumulative rates of 0.39% and 0.48% before
and after 1997 respectively [6].
As the prevalence of transfusion-transmitted diseases
among multitransfused patients is a good indicator of the
safety of the blood supply, our results confirm the
assumption that after 1997 blood transfusions no longer
represented a significant route for the transmission of CD
in the most densely populated area of Brazil.
Conclusion
In conclusion, the prevalence of CD among multitrans-
fused patients declined significantly as a result of the
implementation of multiple interventions aimed to
reduce the transmission of CD in Brazil. Permanent vigi-
lance is essential to identify points that could be further
improved to minimize the risk of transfusion-transmitted
CD such as the accuracy of screening tests.
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